Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN)
A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease. These analogues are licensed for type 2 diabetes, but their efficacy in patients with non-alcoholic steatohepatitis is unknown. We assessed the safety and efficacy of the long-acting GLP-1 analogue, liraglutide, in patients with non-alcoholic steatohepatitis.
Armstrong MJ et al. Lancet. 2016 Feb 13;387(10019):679-90